Pfizer and its much-discussed palbociclib lead the way in the race to cash in on the blockbuster potential of a new pathway to treat breast cancer, but Novartis' rival drug has stealthily closed the gap, promising to compete much sooner than expected.
Canada's Oncolytics Biotech trumpeted some promising late-stage results for its viral head and neck cancer therapy, but a distortion in the company's overall survival data rattled investors, sending its shares down as much as 8.6% on Thursday.
OraSure Technologies is ending a deal with Roche Diagnostics to develop tests that can screen for substance abuse. But the Pennsylvania company has quickly cozied up to a new collaborator: Thermo Fisher Scientific.
Despite some ongoing patent battles and mounting legal trouble, Myriad Genetics remains a heavy hitter in the world of cancer diagnostics, and now the Utah company has struck up a deal with drug developer BioMarin Pharmaceutical to use one of its molecular tests to develop a targeted cancer drug.
Medtronic is touting some positive early data on a stent graft that could expand the patient population for surgery-free endovascular repair, taking advantage of a speedy new FDA pathway set aside for innovative devices.
The European Union began looking for a solution to vaccine instability earlier this year, and is now nearing the end of its search. A decision is expected next month, after which the EU will commit $3 million to support development of the vaccine temperature stability project.
Argos Therapeutics is working to get out from under the shadow of Dendreon and its disappointing Provenge, and now the North Carolina company has the cash it needs to get its kidney cancer candidate through Phase III and prove the promise of its dendritic cell platform.
Moderna Therapeutics is having quite a year, and the Cambridge, MA, biotech just put a $110 million capstone on 2013, raising a colossal new round and riding high on technology that promises to transform the human body into a drug factory.
New Jersey device outfit Svelte Medical Systems finished enrolling patients in a pivotal study of its Integrated Delivery System (IDS) drug-eluting coronary stent, comparing it with Medtronic's Resolute Integrity drug-eluting stent.
Researchers at the Icahn School of Medicine at Mount Sinai Hospital used a virus to deliver genes directly to the heart to reverse heart failure, shrinking an enlarged heart and improving its function.